SELLAS Life Sciences Group, Inc.
(NASDAQ : GALE)

( )
GALE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.08%196.181.2%$557.67m
TSROTESARO, Inc.
0.22%74.2514.4%$534.38m
CELGCelgene Corporation
0.96%70.161.2%$533.98m
GILDGilead Sciences, Inc.
0.34%67.720.9%$508.18m
BIIBBiogen Inc.
0.11%319.791.3%$358.06m
ILMNIllumina, Inc.
1.81%328.903.5%$353.03m
REGNRegeneron Pharmaceuticals, Inc.
-0.50%375.722.6%$262.39m
AAgilent Technologies, Inc.
0.67%71.061.5%$237.22m
VRTXVertex Pharmaceuticals Incorporated
-0.32%173.231.9%$235.67m
ALXNAlexion Pharmaceuticals, Inc.
0.16%114.832.0%$143.36m
SRPTSarepta Therapeutics, Inc.
1.79%125.0015.4%$112.54m
INCYIncyte Corporation
0.28%65.602.5%$104.06m
EXASExact Sciences Corporation
-0.04%69.5225.3%$99.67m
NKTRNektar Therapeutics
-0.63%36.435.5%$97.21m
EXELExelixis, Inc.
-1.78%20.986.4%$82.17m

Company Profile

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. The company was founded on April 3, 2006 and is headquartered in New York, NY.